Related Experiment Video
Updated: Jun 7, 2025
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic
Carson M Quinn1, Prashanth Rajarajan1, Alexander J Gill1
1From the Department of Neurology (C.M.Q., P.R., S.E.C., S.B.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (A.J.G., J.C.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Neurology (H.K., T.E.B., I.K.), NYU Grossman School of Medicine, New York; Department of Neurology (A.B.W., E.A.), University of Colorado School of Medicine, Aurora; Department of Neurology (C.S.d.C., V.B.), Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ; Department of Neurology (J.L., P.C.), Stony Brook University Medical Center, NY; Sidney Kimmel Comprehensive Cancer Center (J.C.M.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Neurology (K.M.G.), Stanford University, CA; Medical Partnership 4 MS+ (MP4MS+) (D.K.), LaBelle, FL.
Background And Objectives:
Immune checkpoint inhibitors (ICIs) are increasingly used against various cancers but are associated with immune-related adverse events (irAEs). Risk of irAEs may be higher in patients with certain preexisting autoimmune diseases, and these patients may also experience exacerbation of the underlying autoimmune disease following ICI initiation. People with multiple sclerosis (MS) have mostly been excluded from clinical trials of ICIs, so data on the safety of ICIs in MS are limited. This study aims to assess the rate of MS activity, as well as neurologic and nonneurologic irAEs in persons with MS treated with ICIs for cancer.
Methods:
Participating sites were invited to this retrospective observational study through the Medical Partnership 4 MS+ listserv. Seven large academic centers participated in the study, each conducting a systematic search of their electronic medical record system for patients with MS and history of ICI treatment. The participating neurologist reviewed each chart individually to ensure the inclusion criteria were met. Demographics and data on MS and cancer history, treatments, and outcomes were abstracted from patient charts using a structured instrument.
Results:
We identified 66 people with MS (median age 66 years, 73% female, 68% not on disease-modifying therapy for MS) who were treated with ICIs for lung cancer (35%), melanoma (21%), or another oncologic indication. During post-ICI follow-up (median: 11.7 months, range 0.2-106.3 months), 2 patients (3%) had relapse or MRI activity, 3 (5%) had neurologic irAEs, and 21 (32%) had nonneurologic irAEs. At the last follow-up, 25 (38%) participants had partial or complete remission of their cancer, while 35 (53%) were deceased.
Discussion:
In this multi-institutional systematic retrospective study of predominantly older patients with MS, most of whom were not on disease-modifying therapy, MS activity and neurologic irAEs following ICI treatment were rare. These data suggest that preexisting MS should not preclude the use of ICIs for cancer in older patients, but the results may not be generalizable to younger patients with active MS. Prospective studies of ICI safety that enroll younger patients with MS are needed.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...